金斯瑞生物科技(01548):传奇宣布于2025年ASH年会上公布报告

智通财经
Dec 07

智通财经APP讯,金斯瑞生物科技(01548)发布公告,传奇生物科技股份有限公司("传奇",为公司联营公司,其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)于2025年12月6日(纽约时间)发布新闻稿宣布于2025年美国血液学会("美国血液学会")年会上通过一项口头报告公布了CARVYKTI(西达基奥仑赛,cilta-cel)在复发或难治性多发性骨髓瘤(RRMM)患者中开展的CARTITUDE-1和CARTITUDE-4研究长期随访的临床及转化研究数据,

以及III期研究CARTITUDE-4的最新结果,还通过六项壁报展示了CARVYKTI在不同亚组中的缓解持久性数据及真实世界研究结果。传奇亦在美国血液学会年会通过口头报告展示了双靶点同种异体CAR-T候选产品LUCAR-G39D的首次人体试验数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10